MediWound Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

MediWound şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

May 07

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Feb 28

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Feb 01

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Dec 18

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Sep 29

MediWound's NexoBrid for thermal burns in children gets EMA review

Sep 20

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Aug 11

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Aug 09

MediWound completes enrollment for interim assessment of mid-stage EscharEx study

Jun 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MDWD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MDWD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

MediWound Piyasaya Karşı Temettü Getirisi

MDWD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MDWD)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (MDWD) (3 yıla kadar)	n/a

Önemli Temettü: MDWD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MDWD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MDWD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MDWD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

MediWound Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

MediWound Ltd. to Report Q3, 2024 Results on Nov 26, 2024

MediWound Is A Healthy Investment

MediWound Ltd. Announces Phase II Head-To-Head Study Evaluating EscharEx®? vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Ltd. Announces Positive Results from the U.S. NexoBrid Expanded Access Protocol (NEXT)

MediWound Ltd. to Report Q2, 2024 Results on Aug 14, 2024

MediWound Ltd. Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

MediWound Ltd. announced that it expects to receive $24.999994 million in funding from Mölnlycke Health Care AB and other investors

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

MediWound Ltd., Annual General Meeting, Jul 09, 2024

MediWound Ltd. to Report Q1, 2024 Results on May 29, 2024

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings released: US$0.74 loss per share (vs US$3.93 loss in FY 2022)

MediWound Ltd. to Report Q4, 2023 Results on Mar 21, 2024

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns

Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Third quarter 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$0.75 loss

MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023

MediWound Ltd. to Report Q3, 2023 Results on Nov 21, 2023

MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

New major risk - Shareholder dilution

MediWound Ltd. Announces U.S. Commercial Availability of NexoBrid®? for the Treatment of Severe Thermal Burns in Adults

High number of new and inexperienced directors

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$27.25

MediWound Ltd. to Report Q2, 2023 Results on Aug 15, 2023

MediWound Ltd. Announces Commercial Launch of NexoBrid®? in Japan

Mediwound Ltd. Announces Positive Results in Its U.S. Phase I/Ii Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

Consensus revenue estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MediWound Ltd. to Report Q1, 2023 Results on May 30, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

MediWound Ltd. Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Price target decreased to US$43.50

MediWound Announces Positive Results in U.S. Phase I/II Study of Mw005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd Gains Marketing Approval of NexoBrid® in India

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

MediWound Ltd. to Report Q3, 2022 Results on Nov 15, 2022

High number of new directors

High number of new directors

MediWound Ltd. Announces Formation of Strategic Advisory Board

MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

Price target increased to US$7.20

MediWound Ltd. Announces European Medicines Agency Validates for Review the Type Ii Variation

MediWound's NexoBrid for thermal burns in children gets EMA review

Consensus revenue estimates fall by 14%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Mediwound Ltd. Announces Management Changes

Price target increased to US$6.90

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

MediWound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns

MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review

MediWound Ltd. to Report Q2, 2022 Results on Aug 09, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MediWound Ltd. Announces Positive Results from Its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

MediWound adds 13% after favorable data for ulcer candidate

MediWound Ltd. Announces Appointment of Tzvi Palash as Chief Operating Officer

MediWound taps Tzvi Palash as COO

Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?

MediWound Ltd., Annual General Meeting, Jul 19, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors

MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex® for the Debridement of Venous Leg Ulcers